The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GLTO | -31.82% | -98.7% | -58% | -99% |
| S&P | +12.65% | +91.73% | +13.89% | +103% |
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.
No news articles found for Galecto.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | 83.3% |
| Market Cap | $4.93M | -67.5% |
| Market Cap / Employee | $0.99M | 0.0% |
| Employees | 5 | -61.5% |
| Net Income | -$3.13M | 19.3% |
| EBITDA | -$3.15M | 16.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.61M | -61.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.40M | 0.0% |
| Short Term Debt | $0.02M | -53.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -92.89% | -35.2% |
| Return On Invested Capital | -83.50% | -12.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.62M | 28.3% |
| Operating Free Cash Flow | -$2.62M | 28.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.28 | 0.28 | 0.37 | 0.51 | -8.27% |
| Price to Tangible Book Value | 0.28 | 0.28 | 0.37 | 0.51 | -8.27% |
| Enterprise Value to EBITDA | 2.50 | 2.47 | 1.26 | 0.40 | -73.67% |
| Return on Equity | -91.6% | -91.3% | -100.0% | -114.8% | 58.11% |
| Total Debt | $1.43M | $1.43M | $1.42M | $1.41M | 4315.63% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
